• Publications
  • Influence
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
It is demonstrated that the effects of risedronate over 3 years on vertebral fracture and BMD are maintained with a further 2 years of treatment, as well as rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 Years of treatment. Expand
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Treatment of postmenopausal osteoporosis by interval IV bolus injections of the bisphosphonate ibandronate was safe and effective in increasing BMD through a dose-dependent inhibition of bone resorption. Expand
A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function
To compare the safety and efficacy of two doses of a new testosterone gel formulation to a permeation‐enhanced testosterone patch for treating men with confirmed low serum testosterone levels, and associated signs and symptoms of hypogonadism. Expand
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
Tiludronate at 400 mg/day for 3 months or 6 months is more effective than the same dosage of etidronate for 6 months in the treatment of Paget's disease. Expand
Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women
It is worthwhile measuring serum vitamin D before starting etidronate therapy and, in case of deficiency, to give vitamin D. Expand
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma
Abstract In a randomized trial of adjuvant chemotherapy, immunotherapy, or immunochemotherapy, 761 evaluable patients with pathological Stage II cutaneous melanoma anywhere on the body or withExpand
Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.
It is suggested that corticosteroid-induced bone loss may be prevented by instituting intermittent cyclical etidronate therapy when high-dose prednisone therapy is begun. Expand
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Results of this extensive evaluation indicate that daily treatment with 5 mg of risedronate sodium is not associated with an increased frequency of adverse GI tract effects, even among patients at high risk for these events. Expand
The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide.
Inhaled corticosteroids affect biochemical bone markers and bone mineral density, but there is a different effect for the two corticosterone evaluated in the present study. Expand
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled,
Risedronate 5 mg/d was associated with the prevention of bone loss at the spine and hip (based on significant increases in BMD in LS and total Fem) and significantly reduced concentrations of uNTx and sBAP compared with placebo (both, P < 0.001). Expand